Thomas Uldrick is an Oncology physician affiliated with Regeneron. OpenAlex indexes 228 publications with 9,658 citations (h-index 47); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
825 Eastlake Ave E
Seattle, WA 981094405
Telephone
206-606-1024Registry record last updated 8 Dec 2017.
Clinical trials
- Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy
Science Translational Medicine
2022 - COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Journal for ImmunoTherapy of Cancer
2021 - Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
Journal for ImmunoTherapy of Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Kimberly
Regeneron
Robert Vitti, MD
Regeneron
Andrew Fontenot, MD
Regeneron
Mihaela Cristea, MD
Regeneron
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”